Effect of <em>BRCA1</em> and <em>XPG</em> mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in subjects with advanced ovarian cancer: exploratory analysis of phase III OVA-301 study

Monk, Bradley

99 - Featured Poster
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in subjects with advanced ovarian cancer: exploratory analysis of phase III OVA-301 study

Monday, March 24, 2014: 7:20 AM

Room 13-16 (Tampa Convention Center)

B. J. Monk¹, P. Ghatage², T. Parekh³, E. Henitz³, R. Knoblauch³, A. Soto Matos-Pita⁴, A. Nieto⁴, Y. C. Park³, D. Ricci³ and A. Poveda⁵
¹University of Arizona Cancer Center, Phoenix, AZ, ²Tom Baker Cancer Centre, Calgary, AB, Canada, ³Janssen Research & Development, Raritan, NJ, ⁴PharmaMar SA, Madrid, Spain, ⁵Fundación Instituto Valenciano de Oncología, Valencia, Spain

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

99 - Featured Poster
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in subjects with advanced ovarian cancer: exploratory analysis of phase III OVA-301 study

99 - Featured Poster Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in subjects with advanced ovarian cancer: exploratory analysis of phase III OVA-301 study

99 - Featured Poster
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in subjects with advanced ovarian cancer: exploratory analysis of phase III OVA-301 study